15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial
Lukas Bethlehem / nature - Nature Medicine, Published online: 02 June 2026; doi:10.1038/s41591-026-04442-2A randomized, single-blind, parallel-group, phase 1b clinical trial compared fecal microbiota transplant or a 15-strain live biotherapeutic product (MTC01) derived from the sam…
AI Summary: A randomized phase 1b trial compared a defined 15‑strain live biotherapeutic product with traditional donor fecal microbiota transplant for recurrent Clostridioides difficile infection and found comparable safety and efficacy. The result supports a manufactured, standardized microbiome therapy as a realistic alternative to donor stool, simplifying logistics and regulation — and making “poop pills” slightly less artisanal.
Related Stories
One hepatitis B drug shows early functional cures in trial / 3 months
Study finds MenB vaccine does not prevent gonorrhea in men / 7 wks
Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 3 months
Triple‑dose early treatment clears HIV in newborn primates study / 20 days
Fridge‑free vaccine advances aim to cut massive vaccine wastage / 26 days
UK begins human testing of first AI-designed 'universal' vaccine / 2 months
Favipiravir shows promise in Lassa fever Phase 2 trial / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Research Funding, Vaccine Safety, Pancreatic Cancer, None and look for the RSS link.
StackHealth Time Machine